Journal article · 2019 · Open access
Alzheimer's disease drug development pipeline: 2019
Alzheimer s & Dementia Translational Research & Clinical Interventions, 5(1), 272–293 · Published 1 January 2019 · DOI 10.1016/j.trci.2019.05.008
In brief
“Alzheimer's disease drug development pipeline: 2019” is a 2019 journal article by Jeffrey L. Cummings and 4 co-authors, published in Alzheimer s & Dementia Translational Research & Clinical Interventions. OpenAlex counts 806 citations as of 15 November 2026, which puts it in the top 1% of works published in 2019 by citations. It is open access under a CC BY licence: the full text is free to read at Alzheimer s & Dementia Translational Research & Clinical Interventions.
- Citations
- 806
- Most cited in
- 2020 (224)
- Field-weighted impact
- 50.73
- References
- 48
- Authors
- 5
Abstract
INTRODUCTION: Alzheimer's disease (AD) has few available treatments, and there is a high rate of failure in AD drug development programs. Study of the AD drug development pipeline can provide insight into the evolution of drug development and how best to optimize development practices. METHODS: We reviewed clinicaltrials.gov and identified all pharmacologic AD trials of all agents currently being developed for treatment of AD. RESULTS: There are 132 agents in clinical trials for the treatment of AD. Twenty-eight agents are in 42 phase 3 trials; 74 agents are in 83 phase 2 trials; and 30 agents are in 31 phase 1 trials. There is an increase in the number of agents in each phase compared with that in the 2018 pipeline. Nineteen agents in trials target cognitive enhancement, and 14 are intended to treat neuropsychiatric and behavioral symptoms. There are 96 agents in disease modification trials; of these, 38 (40%) have amyloid as the primary target or as one of several effects. Eighteen of the antiamyloid agents are small molecules, and 20 are monoclonal antibodies or biological therapies. Seven small molecules and ten biologics have tau as a primary or combination target (18%). Amyloid is the most common specific target in phase 3 and phase 2 disease modification trials. Novel biomarkers (e.g., neurofilament light), new outcomes (e.g., AD Composite Score [ADCOMS]), enrollment of earlier populations, and innovative trial designs (e.g., Bayesian adaptive designs) are new features in recent clinical trials. DISCUSSION: Drug development continues robustly at all phases despite setbacks in several programs in the recent past. Continuing unmet needs require a commitment to growing and accelerating the pipeline.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Cummings, J. L., Lee, G., Ritter, A. R., Sabbagh, M. N., & Zhong, K. (2019). Alzheimer's disease drug development pipeline: 2019. Alzheimer s & Dementia Translational Research & Clinical Interventions, 5(1), 272–293. https://doi.org/10.1016/j.trci.2019.05.008
MLA 9
Cummings, Jeffrey L., et al. “Alzheimer's disease drug development pipeline: 2019.” Alzheimer s & Dementia Translational Research & Clinical Interventions, vol. 5, no. 1, 2019, pp. 272–293. https://doi.org/10.1016/j.trci.2019.05.008.
Chicago
Cummings, Jeffrey L., Garam Lee, Aaron R. Ritter, Marwan Noel Sabbagh, and Kate Zhong. 2019. “Alzheimer's disease drug development pipeline: 2019.” Alzheimer s & Dementia Translational Research & Clinical Interventions 5 (1): 272–293. https://doi.org/10.1016/j.trci.2019.05.008.
Harvard
Cummings, J. L. et al. (2019) ‘Alzheimer's disease drug development pipeline: 2019’, Alzheimer s & Dementia Translational Research & Clinical Interventions, 5(1), pp. 272–293. doi:10.1016/j.trci.2019.05.008.
IEEE
J. L. Cummings, G. Lee, A. R. Ritter, M. N. Sabbagh, and K. Zhong, “Alzheimer's disease drug development pipeline: 2019,” Alzheimer s & Dementia Translational Research & Clinical Interventions, vol. 5, no. 1, pp. 272–293, 2019, doi: 10.1016/j.trci.2019.05.008.
BibTeX
@article{cummings2019alzheimer,
title = {{Alzheimer's disease drug development pipeline: 2019}},
author = {Cummings, Jeffrey L. and Lee, Garam and Ritter, Aaron R. and Sabbagh, Marwan Noel and Zhong, Kate},
journal = {Alzheimer s \& Dementia Translational Research \& Clinical Interventions},
year = {2019},
volume = {5},
number = {1},
pages = {272--293},
doi = {10.1016/j.trci.2019.05.008},
url = {https://doi.org/10.1016/j.trci.2019.05.008}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2019 | 25 | |
| 2020 | 224 | |
| 2021 | 160 | |
| 2022 | 105 | |
| 2023 | 83 | |
| 2024 | 68 | |
| 2025 | 64 | |
| 2026 | 76 |
Its field-weighted citation impact is 50.73: it has been cited 50.73 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Alzheimer's disease
- drug development pipeline
- clinical trials
- disease-modifying therapy
- cognitive enhancement
- neuropsychiatric symptoms
- biomarkers
- neurofilament light chain
Work with this paper
Most-cited papers in Neuroscience
- The Rat Brain in Stereotaxic CoordinatesGeorge Paxinos, CHARLES R. R. WATSON · Elsevier eBooks · 1982 · 52,413 citations
- The assessment and analysis of handedness: The Edinburgh inventoryRichard Charles Oldfield · Neuropsychologia · 1971 · 36,725 citations
- EEGLAB: an open source toolbox for analysis of single-trial EEG dynamics including independent component analysisArnaud Delorme A, Scott Makeig · Journal of Neuroscience Methods · 2004 · 25,302 citations
- The Ecological Approach to Visual PerceptionMarc H. Bornstein, James J. Gibson · Journal of Aesthetics and Art Criticism · 1980 · 22,977 citations
- The Psychophysics ToolboxDavid H. Brainard · Spatial Vision · 1997 · 20,208 citations
Questions about this paper
How do I cite this paper in APA style?
Cummings, J. L., Lee, G., Ritter, A. R., Sabbagh, M. N., & Zhong, K. (2019). Alzheimer's disease drug development pipeline: 2019. Alzheimer s & Dementia Translational Research & Clinical Interventions, 5(1), 272–293. https://doi.org/10.1016/j.trci.2019.05.008
How many times has this paper been cited?
806 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access: read the free full text at Alzheimer s & Dementia Translational Research & Clinical Interventions.
Who wrote this paper?
Jeffrey L. Cummings, Garam Lee, Aaron R. Ritter, Marwan Noel Sabbagh, Kate Zhong.
What is the DOI of this paper?
10.1016/j.trci.2019.05.008. The permanent link is https://doi.org/10.1016/j.trci.2019.05.008.
Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.